Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network…

Overview of attention for article published in Clinical Infectious Diseases, August 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

blogs: 1 blog
policy: 2 policy sources
twitter: 5 X users

bluesky: 2 Bluesky users
podcasts: 1 podcast

Readers on

mendeley: 20 Mendeley

So far, Altmetric has seen 2 Bluesky posts from 2 Bluesky users, with an upper bound of 56 followers.

RP @id-journal.bsky.social: Updated 2023–24 COVID vaccine 🛡️: 54.2% VE vs XBB, 32.7% vs JN lineages; ICU & death odds similar for JN vs XBB hospitalizations. JN may escape immunity more.

Updated 2023–24 COVID vaccine 🛡️: 54.2% VE vs XBB, 32.7% vs JN lineages; ICU & death odds similar for JN vs XBB hospitalizations. JN may escape immunity more.

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.